Crucell forges vaccine pact with Sanofi

The Dutch biotech Crucell will pocket a €10 million up front payment and up to €66.5 million in milestone payments after forging a collaboration and marketing deal with Sanofi Pasteur for its rabies monoclonal antibodies. Sanofi Pasteur has a well developed market for vaccines to combat pre- and post-exposure rabies.

"Adding a next generation rabies treatment to our well-established rabies product range will further position the company as a leading force to help prevent this fatal disease," said Wayne Pisano, the CEO of Sanofi Pasteur. The deal was announced this morning.

- see this release
- read the report from Thomson Financial

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.